← All Twist Bioscience CORP filings

Twist Bioscience CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TWST
Twist Bioscience CORP
10-K: Twist Bioscience Narrows Losses, Boosts Revenue 20% in FY25
Twist Bioscience reported a 20% revenue increase to $376.6 million and significantly reduced its net loss to $77.7 million in fiscal year 2025, driven by strong growth in NGS tools and synthetic genes.
NASDAQ
TWST
Twist Bioscience CORP
10-K: Twist Bioscience Reports Fiscal Year 2024 Results, Highlights Revenue Growth and Strategic Initiatives
Twist Bioscience's 10-K filing for fiscal year 2024 reveals a 28% increase in revenue, driven by strong performance in NGS tools and synthetic genes, alongside a focus on expanding manufacturing capacity and strategic partnerships.